<DOC>
	<DOCNO>NCT01718197</DOCNO>
	<brief_summary>The mission SARP improve understand severe asthma integrate study clinical biological feature evaluate change time . The ultimate goal effort promote good treatment severe asthma .</brief_summary>
	<brief_title>Severe Asthma Research Program ( SARP ) - San Francisco Clinical Site</brief_title>
	<detailed_description>The mission SARP improve understand severe asthma develop good treatment . The SARP gain well understanding asthma endotypes , child adult , define disease molecular cellular level context temporal phenotypic expression disease . To end , SARP investigator utilize mechanistic evoke phenotype approach : 1 ) characterize developmental molecular , cellular physiologic phenotype child adult mild severe asthma , 2 ) elucidate evolve pathobiology pathogenesis severe asthma sub-phenotypes 3 ) compare feature time . This approach involve share longitudinal protocol conduct across participate center include common information SARP participant . Additionally , SARP-SF identify mechanistic research question include shared longitudinal protocol . This explore additional sample collection sputum fluid biopsied tissue collect bronchoscopy . Together , longitudinal mechanistic approach enable prediction phenotype stability/fluctuation pharmacologic responses identification novel , disease-modifying target treatment .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>FEV1 bronchodilator reversibility ≥12 % airway hyperresponsiveness reflect methacholine PC20 ≤16 mg/mL An exception make enrollee whose FEV1 &lt; 50 % predict ( &lt; 70 % child age 6 17 year ) , preclude methacholine challenge test . If bronchodilator reversibility &lt; 12 % participant , diagnosis asthma acceptable investigator sufficient inclusion SARP . Pregnancy characterization phase , Current smoking , Smoking history &gt; 10 pack year ≥30 year age , smoke history &gt; 5 pack year &lt; 30 year age , Other chronic pulmonary disorder associate asthmalike symptom , include ( limited ) cystic fibrosis , chronic obstructive pulmonary disease , chronic bronchitis , vocal cord dysfunction ( sole cause respiratory symptom PI 's discretion ) , severe scoliosis chest wall deformity affect lung function , congenital disorder lung airway , History premature birth 35 week gestation , Unwillingness receive intramuscular triamcinolone acetonide injection Evidence participant family may unreliable poorly adherent asthma treatment study procedure , Planning relocate clinical center area study completion , Any criterion place subject unnecessary risk accord judgment Principal Investigator and/or attend physician ( ) record , Currently participate investigational drug trial . Healthy Controls : Inclusion criterion : Healthy subject age 18y 65y . At least 3 7 subject per center age 35y old . Exclusion criterion History chronic disease affect lung . A history suggestive allergic rhinitis , eczema chronic sinusitis . An improvement FEV1 12 % follow 4 puff albuterol . Smoking history &gt; 10 pack year ≥30 year age , smoke history &gt; 5 pack year &lt; 30 year age , smoke within past year . Respiratory tract infection within past 4 week . Pregnancy . History premature birth ( &lt; 35 week ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Severe Asthma</keyword>
	<keyword>Bronchoscopy</keyword>
</DOC>